[ad_1]
-
Pfizer CEO Albert Bourla told Fox that vaccine-resistant mutants are likely to emerge.
-
According to Bula, Pfizer can create shots for such variants within 95 days of discovery.
-
The CDC director said the virus could be “some mutations” as it evolves to evade the vaccine.
Pfizer CEO Albert Bourla Told Fox News on Tuesday He believed that vaccine-resistant coronavirus variants were “likely” likely to eventually emerge.
“Every time a variant appears in the world, our scientists get it,” Bula said. “And they are studying to see if this variant can escape the protection of our vaccine.
“I haven’t identified it yet, but I think it’s likely that one of them will appear someday.”
Bula added that Pfizer could produce a new version of the vaccine to fight the variants within three months of its discovery.
“We have put in place a process to make a tailor-made vaccine available for this mutant within 95 days of identifying the mutant as a strain of concern,” Bourla said. increase.
This is not the first time this concern about vaccine avoidance has been raised, but experts disagree.
“These vaccines work very well to protect us from serious illness and death, but a major concern is the next mutant that may emerge (potentially a small mutation). ) Is possible Possibility to avoid vaccine“. Rochelle Warrensky, director of the US Centers for Disease Control and Prevention, said at a press conference on July 27.
The UK Government’s advisory board, the Emergency Science Advisory Group, said the rate of virus circulation and infection was high.More opportunities for new variants to emerge.. “
NS CDC estimation As of Monday, 93% of US states were in a “high level of community infection.” New daily cases have more than quadrupled in the past month.
But Angela Rasmussen, a virologist at the University of Saskatchewan in Canada, said: Told the Telegraph Vaccine-resistant strains were unlikely.
“The virus no longer” functions “because it requires so many mutations in peplomers,” Rasmussen said.
Take a look at Bula’s clip here:
Read the original article insider
[ad_2]